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Alternative Hypotheses for the Role of
Promotion in Chemical Carcinogenesis
by Van Rensselaer Potter*
A new protocol for carcinogenesis in rat liver is described in order that confirmatory experiments
might be undertaken concurrently. The basic protocol, designated IPI (initiator + promoter + ini-
tiator), is presented in several alternative forms, including the possible use of X-irradiation as the
initiator. The rationale is discussed in terms of the two-hit somatic mutation theory of Armitage and
Doll, with an initial hit produced by the first dose of initiator and expansion of single cells to sizable
clones by promotion thereby increasing the probability of a second hit by the second dose of initiator.
The question of relevant mutations was taken up and it was proposed that genes for chalones (C) and
for chalone receptors (R) are logical targets for consideration in a two-mutation sequence. Alternative
hypotheses pertaining to promoter action were described in terms of possible mechanisms by which
nonelectrophilic promoters might simulate a second mutation by increasing or decreasing the levels
of a nonchromosomal replicating particle in target cells.
I believe it is worthwhile to discuss rationally de-
rived hypotheses, concepts and beliefs in connection
with the cancer problem because I agree with Pey-
ton Rous, who once said, "Beliefs are important, be-
cause what men believe determines what men do." I
believe that the initiation-promotion model of carci-
nogenesis is the key to the understanding of the na-
ture of cancer.
When making hypotheses we should endeavor to
construct alternative hypotheses and the means to
test them (1). I offer two alternative hypotheses for
the action of the classical promoters, both of which
are based on the assumption of a two-hit or multi-hit
mutational process.
Promotion as Hyperplasia Due to
Blocked Intercellular
Communication
Recently it was proposed that the key to the un-
derstanding of carcinogenesis in terms of initiation
and promotion is the assumption that more than
one relevant mutation is required for the production
of a promotion-independent cell (2,3). It was sug-
gested on the basis of experiments with rat liver
that large numbers of stage I single mutant promo-
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tion-dependent cells could be produced by a single
injection of a low dose of an initiator or a subcarci-
nogenic dose of a complete carcinogen. These "initi-
ated" stage I cells were assumed to be held in a non-
proliferative state by inhibitors (chalones) produced
by surrounding adult hepatocytes (2).
Administration of a promoter of liver carcinogen-
esis, e.g., phenobarbital as demonstrated by Peraino
et al. (4), was assumed to block "intercellular com-
munication" as shown for the phorbol ester pro-
moters by Yotti, Chang and Trosko (5) and by Mur-
ray and Fitzgerald (6) and later confirmed by New-
bold and Amos (7). Williams (8) reported that pheno-
barbital affected communication between liver cells.
Umeda et al. (9) found no effect with Chinese ham-
ster cells [but see Trosko et al. (10)]. That phenobar-
bital expands the population of altered cells in rat
liver has been established by Pitot et al. (11).
Progression through time in the absence of a sec-
ond dose of initiator was assumed to occur by
spontaneous or uncontrolled mutations, with the
probability of a second relevant mutation to pro-
moter independence increasing tremendously as the
population of single mutant promotion-dependent
cells increased under the influence of a promoter
(2,3).
The term "conversion" was used to represent the
experimental production in liver of a second step in
the initiation process by a second dose of initiator
acting on one or more cells in the expanded popula-V. R. POTTER
tion of stage I cells (2). The calculated numbers of
hepatomas caused by two single doses of initiator
separated in time, with no intervening promotion
(one per 1000 rats) was contrasted with the number
of hepatomas caused by two single doses of initiator
separated in time with promotion intervening to
give clones of average size 1000 cells (one hepatoma
per rat). The calculations were based on an initiator
dose that would give 1000 stage I cells per liver (2)
plus the untested assumption that the number of
stage I initiated cells might be comparable to the
number ofy-glutamyltranspeptidase (GGT) clones.
The suggested experiment will be termed the IPI
protocol, indicating an experiment involving two
single injections of an initiator separated by an in-
terval of promotion in the rat liver system. Details
of alternative IPI protocols for rat liver are being
worked out in experiments now in progress.
The purpose of the present essay is to suggest
possible variations on the theme and to document a
basis for suggesting what the relevant mutations
might be, in order to encourage other laboratories
to test concurrently IPI protocols of their own or
identical design since the experiments will require
up to two years to complete. The present commen-
tary is based on experiments involving rat liver,
which are not assumed to be completely analogous
to experiments with mouse skin (12).
That the IPI protocol may be an idea whose time
has come is suggested by the independent publica-
tion of the identical idea in June 1981 by Moolgav-
kar and Knudson (13), who stated "Finally, a
regimen in which application of an initiator is fol-
lowed by several applications of promoter until pap-
illomas appear and then by another application of
initiator should yield more carcinomas than is seen
in classical initiation-promotion experiments. We
are not aware that this experiment has been done.
Such an experiment should probably be done with
preformed carcinogens because cells in the interme-
diate stage may have lost the ability of metabolic
activation of the initiator." Earlier, in emphasizing
the production of a second mutation in the two-
stage hypothesis of Armitage and Doll (14), they re-
marked, "It should be clear by now that our two
stages are not those of initiation and promotion.
Rather, promotion expands the population of initi-
ated cells, thus increasing the probability of the sec-
ond event in one of them." The concordance of the
two independent proposals, one in terms of liver,
and the other in terms of skin, is noteworthy.
It is of historical interest that in a widely quoted
paper on human cancer by Armitage and Doll (14),
in a purely hypothetical discussion that did not pro-
pose the experiment, we find the statement "In the
simplest case, in which the subject is exposed on
two separate and unique occasions to the effect of
the two agents, the resulting incidence of cancer
will be proportional to d2nt where d2 is the dose of
the second promoting agent, andnt is the number of
"changed" cells present at a time t after exposure to
the first initiating agent." (Italics added). It is clear
that in referring to "the second promoting agent"
the authors did not imply that the second agent was
a promoter in the sense of the terminology that is
now widely accepted (15). The second unique occa-
sion would have to be exposure to an initiator in the
simplest case and they did not exclude that the sec-
ond agent could be the same as the first. What is
noteworthy is that for 23 years no one appears to
have reported an experiment stemming from an ap-
plication of the concept. It appears possible that the
experiment, if conceived by anyone, was considered
to be technically unlikely to succeed in skin experi-
ments, while the possibilities in liver experiments
have only recently become more obvious. The possi-
ble relevance to human cancer etiology and to as-
says for carcinogens should not be overlooked.
Suggested Protocols
The aim of the IPI protocol for rat liver is to
carry out the first initiation step with a range of
doses that will produce significant numbers of
clones of altered cells that can be enumerated on a
per liver or per cubic centimeter basis by quantita-
tive stereology (16) using histochemical methods
such as the GGT technique to reveal the clones of
altered cells. The dose of initiator should be nonnec-
rogenic, should produce several thousand altered
clones per liver and should be empirically estab-
lished to be in the subcarcinogenic range as a single
dose with or without subsequent promotion.
For diethylnitrosamine (DEN), considerable data
are available (11), but the protocols are not directly
comparable. In preliminary experiments we have
given single intraperitoneal injections of 5, 15, and
50 mg DEN/kg body weight to 22-day-old weanling
male rats and to 42-day-old rats from the same lot.
After 14 days each group was started on phenobar-
bital and this was maintained for 2, 4 or 6 months.
At 4 months there were about 1100 GGT foci/cm3 in
the rats injected with 50 mg DEN at 22 days of age
and about half that many in the comparable group
injected at 42 days of age (Richards, Campbell, Dast
and Potter, unpublished). Accordingly, the IPI pro-
tocol with 5, 10, 20 and 40 mg DEN at either age
can be recommended, followed by treatment with or
without phenobarbital for 4 months, with a second
injection of DEN over the same dose range after a
2-week period without phenobarbital and mainte-
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nance without phenobarbital for the remaining life
span to quantitate hepatoma production.
If the first injection produced promoter-depen-
dent foci and the second injection produced an occa-
sional promoter-independent cell, the quantification
of the latter should be made over an extended time
span in the absence of promoter in the time period
subsequent to the second injection. If the promoter-
independent cells are really the result of two rele-
vant mutations it should be possible to obtain a
much larger yield of hepatomas if the second injec-
tion is given to animals carrying a large number of
expanded foci that have resulted from promoter
treatment.
Theoretically, there should be an IPI protocol for
a dose of an initiator that will give the following re-
sults (see Fig. 1): I + P, many foci, no hepatomas; I
+ P + I, many foci and several hepatomas; 2I + P,
two times as many foci but no hepatomas; P + 2I,
few small foci, no hepatomas; I + no P + I, few
small foci, no hepatomas. It now appears that the
appropriate doses of DEN at each injection will be
under 10 mg/kg when phenobarbital is used. Thus in
the above protocol, if I = 5 mg/kg in a single injec-
tion, 2I = 10 mg DEN/kg in a single injection.
Where P appears, it signifies promoter treatment
only during the time between two injections of I or
an identical period.
In our preliminary experiments, rats injected at
22 days of age had not only more foci but they ap-
peared sooner than in the case of rats injected at 42
days of age. We have attributed this to the pres-
ence of endogenous promoters, since Moses et al.
have found maximal levels of multiplication-stimu-
lating activity (MSA) in rat serum at birth, de-
creasing to zero by 28 days of age (17) and La-
Brecque et al. have used weanling rat liver for the
isolation of hepatic stimulator substance (HSS)
which they report to be absent in adult rat liver
(18). It is well known that cell proliferation is active
in neonatal and weanling rat liver and nearly com-
plete by 42 days.
Peraino et al. (19) have used even younger rats in
carcinogenesis experiments. They used day-old fe-
male rats injected with approximately 15 mg
DEN/kg body weight and placed on a diet con-
taining 0.05% phenobarbital at 21 days ofage. They
reported that 100% of the animals had foci after 4
weeks and 8 weeks on phenobarbital and five of 24
rats had hepatocellular carcinomas at 8 weeks. Fur-
ther experiments without phenobarbital treatment
are in progress (Peraino, personal communication).
On the basis of the striking effects obtained with
young rats, we have begun an experiment that elim-
inates phenobarbital altogether with an injection of
15 mg DEN/kg body weight at 22 days of age and a
second injection at 42 days of age relying on endo-
genous promoters in the period between 22 and 42
days of age for an IPI protocol. Controls include
both 15 and 30 mg of DEN/kg body weight as single
injections at age 22 days only and at age 42 days
only. If this experiment is based on inappropriate
assumptions, then an IPI protocol based on the
Peraino report (19) should be attempted, with small-
er amounts of DEN, e.g., 2 or 5 mg/kg at each of
two injections, the first at 1 or 10 days of age and
the second at 42 days of age, with no phenobarbital
at any time assuming endogenous promotion.
As pointed out by Moolgavkar and Knudson (14),
the IPI protocol might not be productive with initia-
tors like DEN or any that have to be metabolically
activated. In that case an agent such as methyl- or
ethylnitrosourea might better be used after the ap-
propriate dose range for foci production had been
worked out (20). However, with foci as small as
10-20 cells in diameter, even if the altered cells are
unable to metabolically activate the initiator, sur-
rounding liver cells might carry out the activation
sufficiently to affect cells in the foci (21).
A strong basis for assuming that active metabo-
lites are available to the stage I cells is the report
by Becker (22) that a subcarcinogenic single dose of
dimethylnitrosamine following a three-cycle noncar-
cinogenic regimen of N-2-fluorenylacetamide pro-
duced 12 hepatocellular carcinomas and 40 nodules
in nine rats after one year. This experiment is
worthy ofrepetition.
The IPI protocol for rat liver might very well be
successful using X-irradiation as the initiator, on the
basis of experiments by Cole and Nowell (23) who
combined radiation and CC14 treatment and came
very near to suggesting the IPI protocol.
The Importance of Chalones and
Chalone Receptors
The suggested protocol is based on evidence that
normal adult differentiated tissues produce tissue
specific inhibitors of proliferation (chalones). More-
over the inhibition of metabolic cooperation by pro-
moters (5-10) can also be taken to mean that pro-
moters may act among other ways by diminishing
the ability of normal adult hepatocytes to inhibit the
growth of stage I-initiated cells (Fig. 2).
The word chakone (from the Greek word, to make
slack) was first proposed by Schafer in 1916 (24) to
effect a contrast with the word hormone, but it was
not used in the current sense until 1962 when Bul-
lough (25) first advocated its present use. Iverson
has recently reviewed the extensive literature on
chalones (26).V. R. POTTER
Holley et al. (27) have recently cited 12 examples
of the isolation of growth inhibitory factors from a
variety of mammalian cells and tissues. "Neverthe-
less," they remarked, "there are doubts as to the
significance of endogenous growth inhibitors be-
cause most of the inhibitor preparations have low
specific activity. The inhibitors have been difficult
to purify, and with some preparations the causes of
growth inhibition have, at least in part, turned out
to be trivial." In contrast to some earlier reports
they reported the isolation of two kidney epithelial
cell growth inhibitors that were active in cell cul-
tures at ng/ml concentrations and whose activity was
counteracted by epidermal growth factor (EGF) or
by calfserum.
At about the same time Wang and his colleagues
reported (28) the isolation of an inhibitor for fibro-
blast proliferation and McMahon and Iype (29) re-
ported the preparation of an inhibitor of hepatocyte
proliferation from adult rat liver. The latter factor
has now been reported to be isolated as a protein
with molecular weight of 26,000 (30). Any relation-
ship to the low density lipoprotein isolated by Lef-
fert and Weinstein (31), to the material isolated
from beef liver by Sekas et al. (32), to the mitosis-in-
hibiting protein (MIP) (33) or to the "chalone hepa-
tique" (34) remains to be explained.
The assumption underlying the present discus-
sion is that chalones and chalone receptors exist
and are involved in the carcinogenic process (Fig. 3).
"Peptide hormones induce a host of responses in
their target tissues through selective interactions
with cell-surface receptors" (35-37), and it is reason-
able to assume that the peptide chalones interact
with receptors also. While the term chalone may be
appropriately used in the broadest sense to include
biological effectors that are not peptides, recent
work (27-30) has implicated proteins in the range of
10,000 to 30,000 molecular weight. [Further citations
given by Iverson (26)]. The current emphasis on the
polypeptide "transforming growth factors" (TGF's)
(38) is based on a flood of discoveries in the area of
the peptide hormones and their receptors (35-38),
while advances in terms of chalones and the likeli-
hood that chalone receptors exist have been largely
ignored. In referring to the "ubiquitous role" of re-
ceptors in metabolic regulation Brown and Gold-
stein (37) note that "specific receptors have now
been demonstrated for more than 30 different phys-
iologically important regulatory molecules" in eight
different categories including plasma lipoproteins
but with no reference to chalones as such.
Research on chalone receptors depends on the
availability of pure preparations of appropriate cha-
lones and the development of serum-free growth
media. so that the chalones can be tested in cell cul-
ture systems in the presence of known concentra-
tions of known growth factors with which they may
compete as indicated by Holley et al. (27). The
achievement of all three of these requirements ap-
pears imminent.
Liver Growth Factors
The development of serum-free growth media for
continuous propagation has been accomplished for
many cell lines (39) and may be near at hand for he-
patocytes. At issue is the nature of the hepatocyte
cell line that might be propagated in serum-free
medium and the apparent multiplicity of growth
regulators and nutrients required. At present it ap-
pears that the mass conversion of adult hepatocytes
to a population of proliferating cells in vitro has
never been accomplished. On the other hand several
investigators have developed hepatocyte cell lines
that can be subcultured for many generations
(29,40). Schaeffer (40) in particular has cloned a cul-
ture that originated with cells from livers of 3-day
old rats and has documented the presence of liver-
specific functions and the normal 42 chromosome
diploid karyotype. This clone, designated as RL-PR-
C, remains nontumorigenic for many population
doublings but eventually transforms spontaneously.
Both the early and late passage cells appear to be
useful for the development of serum-free culture
media, with the latter expected to require a less
complex medium (W. Schaeffer, personal communi-
cation).
The complex requirements for the regulation of
the growth of hepatocytes have been studied by
Leffert since 1972 (41,42). In a recent report citing
this experience Leffert and Koch (43) emphasized
the roles of insulin, glucagon and epidermal growth
factor (EGF) and concluded that perhaps the earli-
est event in response to the peptides was an in-
creased Na+ influx which may well be related to the
TGF's (43). They recognized that additional factors
might be involved, referring to publications cov-
ering regulation by "possibly even six blood-borne
peptides." The question of endogenous growth fac-
tors such as multiplication-stimulating factor (MSA)
(17) and hepatic stimulator substance (HSS) (18) pro-
duced by fetal or neonatal liver cells has been re-
ferred to.
Growth of rat hepatocytes in serum-free media
through many passages has so far not been re-
ported although Marceau et al. (45) have studied the
response of both neonatal and adult hepatocytes to
insulin, dexamethasone, triiodothyronine and EGF
in serum-free medium using a fibronectin coated
substratum.
It is clear that past studies have frequently exam-
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ined extracts for inhibitors in the presence of
growth factors and vice versa (32). With the devel-
opment of serum-free media the inhibitors could be
studied in the presence of controlled amounts of
growth factors and the competition for receptors
could be quantified.
The Relevant Mutations
The search for the "relevant" mutations that led
to transformation of normal cells to malignant cells
has gone on for many years (23). Current work has
emphasized the polypeptide "transforming growth
factors" (TGFs) (38) and their activity as kinases
that act to phosphorylate tyrosine moieties in other
kinases and other proteins (44). These discussions
have ignored the question of possible interaction be-
tween TGF's and chalones despite credible reports
that indicate such interaction (27). Moreover, differ-
ent affinities in transformed cells as compared with
normal cells have been suggested (28).
The hypothesis for two-stage carcinogenesis in
terms of chalones and chalone receptors is pre-
sented in its simplest form in Figure 1, and this hy-
pothesis forms the basis for the protocol and hy-
pothesis outlined in Figure 2. It should be empha-
sized that the protocol in no way depends on the hy-
pothesis nor would an increased yield of tumors in
the IPI protocol necessarily support the hypothesis.
Nevertheless, the IPI protocol could provide a use-
ful basis for testing the hypothesis by means of his-
tochemical tests. According to the hypothesis, nor-
mal adult liver cells contain receptors (R) for the
liver-specific chalone (C) that they produce. Such a
chalone has been isolated by McMahon et al. (30) as
Ii 12
R+C+ - R+C- - R-C-
Normal Promoter Promoter
Dependent Independent
FIGURE 1. Simplified hypothesis for two-stage carcinogene-
sis. Symbols as in Fig. 2. The first stage is the single mu-
tant cell, which is operationally defined as requiring the
presence of a promoter in order to proliferate. The second
stage is the double mutant, which is here defined as pro-
moter independent, meaning that it is able to proliferate in
the absence of a promoter and in the presence of any cha-
lones naturally present. The two-stage theories of Mool-
gavkar and Knudson (13) and of Armitage and Doll (14) also
refer to single mutants and double mutants. It is implicit
in any single or double relevant mutant hypothesis that ad-
ditional irrelevant mutations may be present. It is also nec-
essary to point out that mutants in the receptor gene may
cover a spectrum between R- and R+ with receptors that
have varying affinity constants for the matching chalone.
The additional stages shown in Figs. 1 and 2 result from
the operational distinction between a single mutant cell
and a clone of mutant cells (2).
well as by others (26,30-34). DePaermentier et al.
(34) used a differentiated hepatoma (that originated
in my laboratory) for assay purposes while Mc-
Mahon et al. (29,30) used a "normal" liver cell line
similar to that employed by Schaeffer (40) and
showed that their chalone had no effect on several
tumor lines.
From these results it might be inferred that nor-
mal adult liver cells are R+C+ in phenotype, while
some hepatomas are R+C- in genotype and have the
receptor but do not produce sufficient chalone, and
others are R-C- in genotype and neither possess suf-
ficient receptor nor produce sufficient chalone.* If
an R+C- cell is situated in the midst of a population
of normal R+C+ hepatocytes it is logical to assume
that it would be held in a non-proliferating state by
chalone (C) produced by the R+C+ hepatocytes,
which would also restrict each other.
If a promoter acted to block metabolic coopera-
tion or intercellular communication, the R+C+ cells
would still be blocked internally, but the R+C- cells
would no longer be blocked by their neighbors and
would proliferate (1,15).
The hypothetical R+C- promoter-dependent cell is
not assumed to be identical with any of the pres-
ently known "altered cell" phenotypes such as the
GGT-positive or ATPase-negative clones that have
been studied. Their number may be greater or
smaller than the numbers of the other types fol-
lowing initiation and promotion. It seems logical
that if the population of single mutant R+C- cells can
be expanded in the presence of promoter, the possi-
bility of a second mutation yielding the promoter-in-
dependent R-C- stage will be greatly enhanced. His-
tochemical immunofluorescence tests based on
these two phenotypes might reveal the earliest
numbers of such cells in comparison with the num-
bers revealed by present techniques. Such tests
might be developed using fetal and neonatal liver
for controls.
It is possible that the three states proposed in
Figure 1 would bear a regulatory relationship to the
* The studies on the low density lipoprotein (LDL) receptor
by Brown and Goldstein (37) provide evidence that the genes
for the normal or mutant receptors in their studies are allelic
(46), that there is a half-normal number of LDL receptors in
heterozygotes, and that there is a gene dosage effect (37,46).
That a critical level of gene products in a heterozygote cell
might determine the proliferative rate has been proposed by
Trosko and Chang (3) and is here emphasized in connection
with proposed relevant gene products R (for chalone receptor)
and C (for chalone production). Thus when R+ is used it will in-
dicate the homozygous state R +/+ and when R- is used it is
intended to mean the heterozygote +/-. Similarly C+ is the ho-
mozygote +/+ and C- is the heterozygote +/-. The homozy-
gotes for R- and for C- may well exist in some progressed tu-
mors but they are not essential for the present hypothesis.
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presence and activity of the transforming growth
factors (TGF's) as suggested below.
Promotion as the Dilution or
Amplification of a
Nonchromosomal Genetic
Element
The two-hit hypothesis of carcinogenesis has been
widely assumed to imply two mutations in terms of
altered DNA structure, and the "simplest hypothe-
sis" (2) for the role of promoters assumes that their
effect is achieved by expanding the populations of
one-hit cells thereby making a second hit (alteration
in DNA structure) more probable, as outlined in
Figures 2 and 3. This assumption is fortified by the
knowledge that in general the initiators and "com-
plete" carcinogens are electrophiles that alter DNA
structure, while the typical tumor promoters are
not electrophiles and do not form adducts with
DNA moieties (47). In the opening section, promo-
tion as hyperplasia due to blocked intercellular com-
munication (i.e., without alteration in DNA struc-
ture) was presented. Without discarding that hy-
pothesis, we must now consider the alternatives by
which a nonelectrophilic promoter could act to pro-
duce the effect of a second mutation without acting
to alter DNA structure.
Two alternative hypotheses must be considered.
They are not mutually exclusive nor are they incom-
patible with the simplest hypothesis. The first is
based on recent experiments and proposals by Var-
shavsky (48,49) in which the powerful skin tumor
promoter 12-0-tetradecanoyl-phorbol-13-acetate
(TPA) was shown to dramatically increase the inci-
dence of methotrexate-resistant 3T6 mouse cells in
culture (49). It was proposed that the result was due
to the production by TPA of "locus-unspecific" extra
rounds of DNA replication in many different chro-
mosomal domains, of which the production of
greatly increased gene copies for dihydrofolate re-
Promoter-Dependent
Stage I Initiated Cell: Normal Cell:
11 attack
,R + C - -H- mutation
Blocked
by ,_
Promoter
promotion
proliferation
-. Clone of R + C - Cells (Stage 111)
12 attack, mutation
R - C - Promoter-independent
Stage IV Cancer Cell
I proliferation
R - C - Promoter-independent
Stage V Cancer Clone
I progression
DIVERSE MUTANT CLONES
Fi(;URE 2. The IPI protocol with a hypothesis as to the initiator and promoter functions that would fit the fact of their synergistic
action. The symbols R+C+, R+C-, and R-C- represent the normal genome, the single allelic mutant for the chalone, and the mu-
tant for both the chalone receptor (R) and the liver chalone (C). The liver chalone is defined as a product of adult hepatocytes
that inhibits the proliferation of mature or immature hepatocytes. The general hypothesis is that "Cancer results from two or
more relevant mutations; promoters enhance proliferation of cells with one relevant mutation, thereby increasing the probabil-
ity of obtaining a cell with two relevant mutations" (2). The specific hypothesis is that mutations in R and C are relevant, here
proposed for the first time. I, indicates a single injection of a compound that can be classified as an initiator and that produces
structural changes in DNA. I! indicates a second treatment by the same or another initiator, also as a single injection. Experi-
ments using radiation in two doses separated by an interval of promotion might be ideal.
R+C++
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(Consists of Two Injections of Initiator Separated by a Period of Promotion)
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FIGURE 3. A new protocol for chemical carcinogenesis in rat liver. The protocol will be referred to as the IPI since it consists of
two injections of an initiator separated by a period of promotion (2). The stages are as described earlier (2). Stage II is omitted
here, since operationally stage II is the point at which promoter is discontinued to determine how many clones are at stage III.
ductase (DHFR) was simply a convenient model.
The ability to prevent inappropriate DNA replica-
tion leading to the generation of "extrachromosomal
copies of cellular genes" (49) was assumed to be
under metabolic control, in other words it might be
said to be controlled by intercellular communication.
The "constitutive" production of growth factors by
tumors (38,50) might, according to the Varshavsky
model, be brought about by inappropriate gene am-
plification in the presence of a promoter, or by a
"second mutation" needed for "promoter indepen-
dence" as in Figures 2 and 3.
A second hypothesis for the production of a rele-
vant "second mutation" by a nonelectrophile tumor
promoter resembles the Varshavsky model insofar
as it assumes the existence of extrachromosomal
copies of genetic particles. It was pointed out in
1950 (51) that if such elements exist, their total loss
(a "second mutation") could be brought about by a
speeding up of cell proliferation relative to particle
proliferation or by a slowing of particle proliferation
relative to cell proliferation. The latter could be the
extra property of promoters in addition to the pro-
duction of hyperplasia. The 1950 proposal was based
on a model system studied by Sonneborn and by his
student Preer. I have used tables by Preer (52) to
construct a chart (Fig. 4) showing the total loss of a
nonchromosomal replicative particle under condi-
tions that permit cell replication to exceed particle
replication assuming a random (Poisson) distribution
of particles between two daughter cells. If a lost
particle were the source of control for growth factor
production, the latter would become constitutive
(38,50), and the effect would be that of a second mu-
tation.
The Blocked Ontogeny Hypothesis
and the Morris Hepatomas
In an earlier report (53) it was suggested that the
TGFs are fundamentally the product of embryonic
cells or stem cells, in any case cells that actively
proliferate, while chalones are the products of non-
proliferative cells that are either terminally differ-
entiated or near that stage. It was further proposed
on the basis of numerous proteins present as so-
called fetal and adult forms of homologous proteins
such as y-globin (fetal) and P-globin (adult) that the
production of chalones might somehow not only sup-
press proliferation but suppress the production of
TGF's as suggested above.
Thus a concept of hepatocyte maturation can be
presented as in Figure 5 in which the hepatocyte
genotype is R+C+ but the two genes are unex-
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TRANSFORMATION OF CELL TYPE
PARAMECIUM-K/LLER TO 'SENS5T/vE
FIGURE 4. An experimental model of the absolute loss of a
replicating particle from cells that can divide relatively
faster than the particles are able to divide. The model is an
alternative hypothesis for a possible "second mutation" by
a nonelectrophilic tumor promoter that could slow the
replication of a nonchromosomal replicative particle. The
experiments were carried out by Preer (52), whose data
were used to prepare the above chart. See also Potter et
al. (51). The organism was Paramecium aurelia (Variety 2).
Preer estimated the starting number of "killer" particles
(K. kappa) at 256 (M) and the growth rate as logarithmic at
1.9 times per day for particles and 3.3 times per day for
the cells. Distribution of particles in dividing cells was as-
sumed to be random and was calculated according to the
Poisson equation P0 = e -m, where P0 is the number of
cells with no particles, and m is the mean number of
particles per cell. In the chart, the dashed lines were
calculated. The identity and function of the Kappa par-
ticles is not relevant to the model as such.
pressed in the fetal hepatocyte, which is accordingly
R-C- in phenotype. Unstated in Figure 5 is the
strong possibility that the fetal hepatocyte is GF' in
phenotype as suggested earlier (53). It is further
proposed that the phenotype changes to R+C- and fi-
nally to R+C+ as maturation proceeds, and that in
the case of liver these phenotypic changes are re-
versible in order to facilitate liver regeneration
after partial hepatectomy.
Finally, in Figure 6 it is proposed that the spec-
trum of Morris hepatomas includes some that are
R+C- and some that are R-C-. The former would re-
quire a single mutation and the latter would require
two mutations. The R+C- type would be highly dif-
ferentiated, subject to some degree of control by
the host, and have receptors responsive to chalones
(34) and as another example, to glucagon, which we
have shown (54). The R-C- type would be poorly dif-
ferentiated, rapidly growing, and unresponsive to
the liver chalone (29,30).
The designations R+ and R- in Figures 1-5 repre-
Fetal
Hepatocyte
Adult
Hepatocyte
Phenotype R - C- R + C - *R+R+C+
Genotype R+C+ --R+C+ ---R+C+
FIGURE 5. The developmental stages of normal hepatocytes.
Symbols as in Fig. 2. There are many differences between
fetal hepatocytes and adult hepatocytes and it is here
assumed that the former do not express either the R or
the C gene, while the latter express both. It is also
assumed that at least one intermediate stage occurs and
that the R+C+ phenotype can retrodifferentiate to the
earlier forms during liver regeneration, and then undergo
"reontogeny."
Phenotype
= Genotype
FIGURE 6. Blocked ontogeny in Morris hepatomas. Symbols
as in Fig. 2. The curved arrows represent mutational
alterations in either or both the R and C genes. Depending
on the mutations there could be blocked or partially
blocked ontogeny (53) at either the R-C- or the R+C- stage.
sent in the simplest case cells that are either posi-
tive or negative but it must be anticipated that
there will be a spectrum of affinity constants that
will include receptors that are not R- but that have
a weak affinity for the normal chalone. Moreover,
the production of chalone will not be a constant but
may even vary on a diurnal basis as is the case for
the hepatic stimulatory substance (18).
Conclusion
As stated earlier, the advocacy of the IPI proto-
col is not dependent upon the concepts described.
What needs to be emphasized is the benefits that
will accrue from the cultivation of normal and trans-
formed hepatocytes in serum-free culture in the
presence of known concentrations of pure growth
factors and chalones. Today the amino acid se-
quence is known only for EGF (55), but the need is
for the sequences of all the peptide growth and
transforming factors and for the peptide chalones in
order to detect homologies, which must form the
basis of interaction and competition (53). With
serum-free cultures (39) and pure GFs and chalones
(27), the receptors and their mechanism of action
(37,46) can be studied. These studies at the molecu-
lar level are needed to finally understand the role of
initiation and promotion in carcinogenesis.
The authors work was supported in part by grants CA-
07175, CA-22484, and CA-17334 from the National Cancer In-
stitute.
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Figures 1 and 2 and portions of the text have been previ-
ously published (15) and are reproduced here with permission
from IRL Press, Ltd., London.
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